Sfondo Header
L'angolo del dottorino
Search the site... Advanced search
✖

Diabetes and cardiovascular disease

Diabetes mellitus alters cardiovascular risk through exposure to hyperglycemia, associated metabolic abnormalities, and progressive damage to blood vessels, the myocardium, the autonomic nervous system, and the kidneys. Its consequences include coronary artery disease, ischemic stroke, peripheral artery disease, and heart failure, through mechanisms that overlap but are not identical. Prevention therefore requires treatment that extends beyond blood glucose normalization alone.

Type 2 diabetes is frequently associated with insulin resistance, visceral adiposity, hypertension, and atherogenic dyslipidemia. In type 1 diabetes, insulin deficiency resulting from the destruction of beta cells, usually autoimmune, predominates; disease duration, glycemic control, and nephropathy are especially important prognostic factors. Increased risk is not uniform: a young person with a recent diagnosis and no organ damage is not equivalent to someone with decades of disease, albuminuria, and a previous myocardial infarction.

Three domains guide assessment: atherosclerosis, heart failure, and kidney disease. Contemporary treatments can protect one or more of these domains even when their effect on HbA1c is modest. However, indications depend on the type of diabetes, the population studied, kidney function, safety, and demonstrated outcomes; glucose-lowering medications should not all be regarded as cardiovascularly equivalent.

Etiopathogenesis and cardiovascular pathophysiology

Chronic hyperglycemia promotes glycation of proteins and lipids, formation of advanced glycation end products, oxidative stress, and activation of intracellular pathways that alter the endothelium and extracellular matrix. Interactions between glycation end products and their receptors sustain inflammatory responses; changes in collagen may increase vascular and myocardial stiffness. The duration of exposure contributes to injury and to the delayed benefits of early control.

In type 2 diabetes, insulin resistance is associated with abnormal lipid fluxes, increased hepatic lipoprotein production, and altered substrate utilization. ApoB may be elevated relative to LDL-C, while increased triglycerides and reduced HDL-C indicate an unfavorable metabolic profile. Retention of atherogenic particles in the arterial wall remains a central cause of atherosclerosis: diabetes amplifies the biological context without making LDL a secondary therapeutic target.

Endothelial dysfunction impairs vasodilation, regulation of inflammation, and interactions with circulating cells. Nitric oxide availability decreases and vascular wall stress increases. Hypertension and kidney damage aggravate the process; normal blood glucose on a single day does not reverse the effects of previous exposure. Vascular protection requires sustained interventions targeting several causal pathways.

Diabetes is associated with increased platelet reactivity and changes in coagulation and fibrinolysis. This environment may favor thrombotic consequences when a plaque becomes complicated, but it does not make anticoagulation appropriate in the absence of a specific indication. Antiplatelet treatment must also be distinguished between secondary and primary prevention because bleeding risk remains clinically relevant.

Coronary artery disease may be diffuse and multivessel, involving distal segments and the microcirculation. Epicardial stenosis is not the only possible cause of ischemia: microvascular dysfunction and impaired flow reserve may contribute to symptoms and prognosis. Anatomy, ventricular function, and disease extent influence the choice of revascularization, beyond the mere presence of a diabetes diagnosis.

In the myocardium, excessive lipid availability, reduced flexibility in substrate utilization, mitochondrial abnormalities, and fibrosis may impair relaxation and function. Diabetes-associated cardiomyopathy describes myocardial involvement that cannot be fully explained by coronary artery disease, hypertension, or valvular disease; in practice, these conditions often coexist and must be investigated. No single echocardiographic finding can establish its origin by itself.

Heart failure may develop with reduced, mildly reduced, or preserved ejection fraction. Obesity and hypertension favor the preserved-ejection-fraction phenotype, while myocardial infarction and ischemia contribute to systolic dysfunction; both pathways may occur in the same patient. Diabetes increases vulnerability to congestion and hospitalization, and heart failure complicates management of volume status, kidney function, and metabolic medications.

Autonomic neuropathy can alter heart rate, the response to exercise, perception of ischemia, and blood pressure regulation. Resting tachycardia, reduced heart rate variability, and orthostatic hypotension are possible manifestations that must be distinguished from other causes. Ischemia may present with less typical symptoms, but it is incorrect to claim that every patient with diabetes experiences silent myocardial infarction. Greater attention should be paid to the range of symptoms, without replacing clinical assessment with indiscriminate invasive screening.

Nephropathy amplifies risk through blood pressure and volume disturbances, inflammation, endothelial dysfunction, and metabolic abnormalities. Albuminuria and reduced eGFR provide complementary information: kidney disease can be present without marked albuminuria, and increased urinary albumin excretion can precede loss of filtration. Their significance extends beyond selecting a drug dose, as they define an important part of prognosis.

Microvascular complications, such as retinopathy and neuropathy, may indicate prolonged exposure and influence overall risk, without simply being a smaller-scale form of atherosclerosis. In the foot, neuropathy, deformity, infection, and ischemia interact to produce complex lesions. Pain may be diminished precisely in the patient with more severe damage, making periodic examination essential.

Glycemic control primarily modifies microvascular risk and, when started early and maintained, may provide long-term cardiovascular benefits. In DCCT/EDIC, previous intensive treatment of type 1 diabetes was associated with fewer events during follow-up, supporting the importance of early exposure to effective control. In patients with advanced type 2 diabetes, however, pursuing near-normal values with strategies carrying a risk of hypoglycemia does not automatically produce the same result: age, disease duration, and treatment approach are decisive.

Clinical manifestations, medical history, and physical examination

The clinical history should establish the type and duration of diabetes, age at onset, HbA1c trends, hypoglycemic episodes, treatments, and complications. A recent diagnosis of type 2 diabetes does not necessarily imply brief exposure, because the unrecognized phase may have lasted years. Insulin treatment does not automatically mean type 1 diabetes: insulin may also be needed in type 2 or other forms.

The cardiovascular history investigates angina and ischemic equivalents, dyspnea, reduced exercise tolerance, palpitations, syncope, and previous events. Fatigue or atypical pain must not automatically be attributed to metabolic disease. Recent chest pain, acute dyspnea, or a neurological deficit requires urgent assessment; waiting for the next diabetes follow-up is inappropriate when an acute event is suspected.

Orthopnea, edema, rapid weight gain, and a progressive decline in activity suggest heart failure. Comparison with usual functional capacity is often more informative than a generic report of tiredness. Obesity, kidney disease, or anemia broadens the differential diagnosis but may also increase the likelihood of several concurrent causes.

Assessment for peripheral artery disease includes claudication, rest pain, slowly healing lesions, and previous revascularization procedures. Classic symptoms may be absent in patients with limited mobility or neuropathy. Inspection of the feet, temperature, skin integrity, and pulses are therefore essential parts of the examination, not optional checks dependent on the presence of pain.

Examination includes blood pressure, including standing measurements when indicated, heart rate and rhythm, weight, and signs of congestion. Bruits, diminished pulses, edema, and evidence of neuropathy are assessed. Evaluation of vision, manual dexterity, and functional independence helps establish treatment safety, particularly if treatment requires glucose monitoring and multiple administrations.

Review of smoking, diet, and adherence also considers costs, access to medications, understanding of the regimen, and fear of hypoglycemia. Complex prescribing can lead to missed doses or duplication. Risk depends on the treatment actually taken and maintained; appropriate simplification and educational support are therefore components of cardiovascular prevention.

Investigations and diagnosis of associated conditions

Outside pregnancy, diagnostic criteria for diabetes include fasting plasma glucose of at least 126 mg/dL, a two-hour plasma glucose of at least 200 mg/dL after a 75-g oral glucose load, or HbA1c of at least 6.5%, equivalent to 48 mmol/mol, measured using an appropriate method. Random plasma glucose of at least 200 mg/dL is diagnostic in the presence of classic symptoms or a hyperglycemic crisis. In the absence of unequivocal hyperglycemia, confirmation with a second abnormal result is required according to the recommended diagnostic pathway.

HbA1c reflects average glycemic exposure but may be affected by conditions that alter hemoglobin or red blood cell survival, including certain anemias, hemoglobinopathies, transfusions, and advanced kidney disease. Significant discordance with measured glucose levels requires investigation. Continuous glucose monitoring provides information on variability and hypoglycemia to guide management but does not automatically replace standard diagnostic tests.

Stress hyperglycemia may occur during an acute event. HbA1c and reassessment after stabilization help distinguish it from preexisting diabetes, without denying its prognostic significance. Classification of diabetes type may require autoantibody testing or C-peptide when the history and phenotype are uncertain. These tests are not necessary for every adult with a typical presentation, but they help avoid inappropriate treatment in atypical cases.

Cardiovascular laboratory assessment includes a lipid profile and kidney function, electrolytes according to treatment, and the urinary albumin-to-creatinine ratio. Non-HDL cholesterol and apoB are useful when triglycerides, obesity, or very low LDL values produce discordance. Measurement of Lp(a) adds information on inherited risk. Persistent renal abnormalities require staging, whereas a single result during infection or dehydration does not automatically establish chronic kidney disease.

The diagnosis of coronary artery disease follows the clinical question. ECG and cardiac biomarkers are essential when an acute event is suspected; anatomical or functional imaging is selected during chronic assessment according to clinical likelihood, symptoms, kidney function, and technical feasibility. Diabetes does not make routine periodic ischemia screening mandatory for all asymptomatic individuals whose risk factors are already adequately treated: testing should be expected to change management.

For heart failure, symptoms, natriuretic peptides, and echocardiography are considered together. Obesity can lower peptide levels and kidney disease can increase them, so values are not interpreted in isolation. In selected pathways, abnormal biomarkers in still-asymptomatic people may prompt structural and functional assessment. Ejection fraction, filling pressures, valve findings, and right ventricular assessment help define phenotype and treatment.

Suspected limb artery disease can be investigated using the ankle-brachial index and duplex Doppler ultrasound. Arterial calcification and noncompressibility, more common in diabetes and nephropathy, can falsely elevate the index; toe pressures or additional methods can help in discordant cases. Ulcers, ischemic pain, or signs of infection require assessment within a timeframe appropriate to the threat to the limb, without merely waiting for glycemic control to improve.

The differential diagnosis of dyspnea and tachycardia includes anemia, respiratory disease, infection, thyroid dysfunction, hypoglycemia, and deconditioning. Autonomic neuropathy is considered after assessing competing causes and medications. A metabolic label must not become a universal explanation for any cardiovascular symptom.

Risk stratification and assessment of organ damage

Guidelines distinguish documented cardiovascular disease, severe organ damage, and diabetes without either condition. A previous myocardial infarction, atherosclerotic stroke, or peripheral artery disease identifies secondary prevention and changes treatment intensity. Significant nephropathy and combinations of microvascular complications may place a patient in a very-high-risk category even before a macrovascular event.

In type 2 diabetes without known atherosclerosis or severe organ damage, SCORE2-Diabetes can refine risk estimates between the ages of 40 and 69 years, in European populations and settings for which it has been validated and calibrated. It combines diabetes-specific factors, including age at diagnosis, HbA1c, and kidney function, with conventional risk factors. It should not be transferred to type 1 diabetes or applied indiscriminately outside its intended age range. Ten-year risk does not capture lifetime risk in full.

Albuminuria must be interpreted together with eGFR and their evolution. Reduced filtration can have causes other than diabetes, especially in the presence of hematuria, rapid decline, or an atypical presentation. Accurate nephrological diagnosis affects prognosis and treatment. Retinopathy and neuropathy complete the assessment but should not be considered sufficient evidence that every renal abnormality is diabetic in origin.

Heart failure risk requires specific attention: diabetes duration, nephropathy, hypertension, obesity, and a cardiac history may make it relevant even when an atherosclerotic risk model appears less concerning. This distinction explains why treatment may be indicated to prevent hospitalization or kidney disease progression without depending solely on estimated myocardial infarction and stroke risk.

Assessment of frailty and hypoglycemia modifies treatment targets. Falls, cognitive impairment, irregular meals, kidney disease, and insulin or sulfonylurea use increase the likelihood of adverse events. An intensive regimen that appears beneficial in theory can become harmful if it causes recurrent hypoglycemia or hypotension. Decisions must integrate life expectancy, function, and preferences without withholding well-tolerated protective treatments.

In type 1 diabetes, glycemic exposure, duration, nephropathy, and other factors are assessed using appropriate tools. Cardiovascular evidence obtained in type 2 diabetes cannot automatically be extrapolated to adjunctive drugs in type 1. In particular, insulin deficiency changes the risk of ketoacidosis and requires a distinct approach to safety.

Integrated treatment and cardiovascular prevention

The guiding principle is multifactorial risk reduction. Diet, physical activity, and smoking cessation accompany treatment of blood pressure, lipoproteins, and hyperglycemia, together with therapies for cardiac and kidney damage. Steno-2 showed that a coordinated intervention targeting multiple factors in patients with type 2 diabetes and microalbuminuria can improve long-term outcomes. The program's benefit cannot be attributed to a single isolated variable.

For many adults, an HbA1c below 7% is a reference target, to be individualized according to disease duration, comorbidities, hypoglycemia risk, and ability to manage treatment. Tighter control may be appropriate in young people with long life expectancy if it can be achieved safely; frailty and advanced disease may require less intensive targets. Targets should also account for time spent in hypoglycemia and glycemic variability when monitoring allows.

The ACCORD trial highlighted the limitations of a very aggressive strategy in high-risk type 2 diabetes: the intensive arm was stopped because of excess mortality. This result concerns the study population and treatment strategy and does not show that glycemic control is useless. Rather, it supports avoiding automatic decisions and distinguishing early prevention, advanced disease, and drugs with different safety profiles.

SGLT2 inhibitors supported by relevant evidence reduce heart failure hospitalizations and progression of kidney disease in defined populations. In type 2 diabetes with heart failure or nephropathy, they are considered for organ protection even when HbA1c is already satisfactory and regardless of previous metformin use. Cardiorenal benefits may persist when glucose-lowering efficacy declines at low eGFR; initiation and continuation must nevertheless respect the specific drug's thresholds and indication.

In EMPA-REG OUTCOME, empagliflozin improved cardiovascular outcomes in people with type 2 diabetes and established cardiovascular disease. Subsequent programs focused on heart failure and nephropathy broadened understanding of this drug class, including beyond diabetes. The effect is not interpreted solely as a consequence of a few tenths of a percentage point in HbA1c: natriuresis, hemodynamic and renal changes, and other mechanisms contribute, without any single explanation fully accounting for the benefit.

Safe use of SGLT2 inhibitors requires attention to volume depletion and ketoacidosis, which may occur without markedly elevated blood glucose. Prolonged fasting, acute illness, surgery, and inappropriate insulin reduction are relevant situations; temporary interruptions and instructions are tailored to the drug and procedure. Genital infections and foot condition require assessment. Given the risk of ketoacidosis, indications established in type 2 diabetes are not automatically extended to type 1.

GLP-1 receptor agonists with proven benefit are particularly relevant in type 2 diabetes with atherosclerosis or high risk, and may provide weight reduction and other advantages. Choice depends on evidence for the individual agent, kidney function, tolerability, and clinical needs. Reducing atherosclerotic events is not the same as preventing heart failure hospitalizations, and the two protective drug classes may address complementary needs.

The SOUL trial demonstrated cardiovascular benefit with oral semaglutide in people with type 2 diabetes at high risk because of atherosclerosis, nephropathy, or both: the primary outcome occurred in 12.0% versus 13.8% with placebo, with a hazard ratio of 0.86. FLOW demonstrated improvement in clinically important kidney outcomes with subcutaneous semaglutide in type 2 diabetes with chronic kidney disease. Formulation, dosage, population, and endpoints must remain distinct.

In SURPASS-CVOT, tirzepatide was compared with dulaglutide, an active treatment with established cardiovascular efficacy, in patients with type 2 diabetes and atherosclerosis. It met the noninferiority criterion for the primary cardiovascular composite outcome; presenting this result as proof of superiority for the same endpoint would be incorrect. Greater reductions in body weight or HbA1c do not automatically establish superiority for clinical events.

Combining cardiorenal therapies may be appropriate when complementary indications persist, but regimens should not simply accumulate medications without assessing benefit, cost, tolerability, and volume status. Metformin remains useful for metabolic control in many patients; kidney function and acute illnesses guide its use. It does not replace an indicated organ-protective treatment and should not be continued in circumstances where risk, such as severe renal impairment or acute hypoxia, makes its use inappropriate.

Insulin therapy is indispensable in type 1 diabetes and may be necessary in type 2, particularly in marked hyperglycemia, catabolism, or inadequate glycemic control. Its use requires hypoglycemia prevention and adjustment for meals, activity, and kidney function. Sulfonylureas also carry a hypoglycemia risk that must be considered; thiazolidinediones can cause fluid retention and are problematic in heart failure. Among DPP-4 inhibitors, the signal of increased heart failure hospitalizations with saxagliptin requires careful selection according to clinical context.

Blood pressure should be controlled using reliable measurements and tolerable targets. The 2024 ESC guidelines propose a systolic pressure of 120–129 mmHg for many treated adults when achievable, with adjustments for frailty, orthostatic hypotension, and other circumstances. ACE inhibitors or angiotensin receptor blockers are particularly relevant with albuminuria and in several cardiovascular settings; additional classes are used as needed. An ACE inhibitor and an angiotensin receptor blocker should not routinely be combined.

In albuminuric kidney disease associated with type 2 diabetes, finerenone may reduce renal and cardiovascular risk in appropriate patients, in addition to recommended treatment, with potassium and eGFR monitoring. FIDELIO-DKD demonstrated kidney benefit in a defined population. FINEARTS-HF also demonstrated a reduction in the composite of worsening heart failure events and cardiovascular death in mildly reduced or preserved ejection fraction; this finding concerns a different setting and must be applied according to the relevant indications and authorizations. Mineralocorticoid receptor antagonists are not combined without a specialist rationale.

Lowering LDL cholesterol is central to prevention. Under European recommendations, very high risk generally calls for LDL-C below 55 mg/dL with at least a 50% reduction, and high risk for below 70 mg/dL with a similar percentage reduction. The category does not depend solely on the diagnosis of diabetes. A statin at the necessary intensity, ezetimibe, and further treatments are combined according to response and tolerability; apoB and non-HDL cholesterol can assess residual particle burden in discordant profiles.

For triglycerides, glycemic control, body weight, alcohol, and secondary causes are crucial. In selected high-risk patients already receiving a statin, icosapent ethyl may offer cardiovascular benefit; this evidence does not extend to every omega-3 formulation. The neutral PROMINENT result with pemafibrate underscores that reducing triglycerides alone does not demonstrate protection from events. Severe elevations instead require an approach also aimed at preventing pancreatitis.

Antiplatelet therapy is indicated for secondary prevention and after procedures according to cardiovascular recommendations, with duration and combinations adapted to bleeding risk. In primary prevention, ASCEND demonstrated a reduction in vascular events with aspirin accompanied by increased bleeding: diabetes alone does not justify universal prescribing. Atrial fibrillation requires a separate assessment for anticoagulation; antiplatelet agents are not an equivalent substitute.

Treatment of heart failure follows its phenotype. With reduced ejection fraction, foundational therapies include renin-angiotensin system modulation or an ARNI, an appropriate beta-blocker, a mineralocorticoid receptor antagonist, and an SGLT2 inhibitor, with diuretics for congestion and additional interventions where indicated. With preserved ejection fraction, congestion, comorbidities, and mechanisms supported by specific evidence are addressed. Improving HbA1c does not replace this approach, just as body weight alone cannot automatically distinguish congestion from adiposity.

Revascularization decisions are based on anatomy, ischemia, symptoms, ventricular function, and procedural risk. In diabetes with an appropriate multivessel disease pattern, surgery may offer advantages over a purely percutaneous approach, but the choice requires multidisciplinary assessment rather than a rule independent of anatomy. Nephropathy, frailty, and infection risk affect preparation. Systemic prevention continues after the procedure because treatment of a stenosis does not eliminate diffuse disease.

Follow-up integrates glycemic targets, blood pressure, lipids, kidney function, potassium, and albuminuria as appropriate to treatment, together with foot and retinal assessment, symptoms, and self-management capacity. Acute illness, fasting, and hospitalization require a temporary medication plan and organized resumption after stabilization. Medication reconciliation prevents appropriate interruptions lasting a few days from becoming unintended permanent discontinuations of beneficial protection.

Prognosis and complications

Prognosis depends on duration, damage, and treatment, not on a single HbA1c measurement. Atherosclerosis, heart failure, or nephropathy identifies risks that may persist even after substantial improvement in glycemic control. Conversely, early, sustained prevention can markedly alter the course of disease, especially when the principal exposures are controlled simultaneously.

Macrovascular complications include myocardial infarction, stroke, and limb ischemia, with possible recurrence, amputation, and loss of independence. Microvascular impairment may increase vulnerability and care complexity. In the foot, infection and ischemia can progress rapidly even with little pain; prevention requires risk identification, skin care, and timely access to appropriate expertise.

Heart failure and kidney disease progression mutually reinforce hospitalizations, functional decline, and therapeutic difficulties. Falling eGFR or new signs of congestion should prompt reassessment of causes, medications, and volume status. Wider availability of protective treatments makes early recognition useful, rather than waiting until an advanced stage or until glycemic control deteriorates.

Iatrogenic complications include hypoglycemia, hypotension, and dehydration, as well as ketoacidosis and electrolyte disturbances in predisposed settings. Cardiovascular risk reduction must be achieved while preserving safety and function. An effective plan integrates evidence, individual circumstances, and continuity, adapting as disease evolves instead of pursuing the same numerical targets indefinitely.

References
  1. Marx N et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. European Heart Journal. 2023;44(39):4043–4140.
  2. American Diabetes Association Professional Practice Committee for Diabetes. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S27–S49.
  3. American Diabetes Association Professional Practice Committee for Diabetes. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S216–S245.
  4. American Diabetes Association Professional Practice Committee for Diabetes. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S246–S260.
  5. SCORE2-Diabetes Working Group and the ESC Cardiovascular Risk Collaboration. SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe. European Heart Journal. 2023;44(28):2544–2556.
  6. McEvoy JW et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. European Heart Journal. 2024;45(38):3912–4018.
  7. Mach F et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. European Heart Journal. 2025;46(42):4359–4378.
  8. Vrints C et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. European Heart Journal. 2024;45(36):3415–3537.
  9. Mazzolai L et al. 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases. European Heart Journal. 2024;45(36):3538–3700.
  10. Borén J et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal. 2020;41(24):2313–2330.
  11. Gaede P et al. Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes. The New England Journal of Medicine. 2008;358(6):580–591.
  12. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group. Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes. The New England Journal of Medicine. 2005;353(25):2643–2653.
  13. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of Intensive Glucose Lowering in Type 2 Diabetes. The New England Journal of Medicine. 2008;358(24):2545–2559.
  14. Zinman B et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. The New England Journal of Medicine. 2015;373(22):2117–2128.
  15. McGuire DK et al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. The New England Journal of Medicine. 2025;392(20):2001–2012.
  16. Perkovic V et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. The New England Journal of Medicine. 2024;391(2):109–121.
  17. Nicholls SJ et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. The New England Journal of Medicine. 2025;393(24):2409–2420.
  18. Bakris GL et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. The New England Journal of Medicine. 2020;383(23):2219–2229.
  19. Solomon SD et al. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. The New England Journal of Medicine. 2024;391(16):1475–1485.
  20. Bhatt DL et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. The New England Journal of Medicine. 2019;380(1):11–22.
  21. Das Pradhan A et al. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. The New England Journal of Medicine. 2022;387(21):1923–1934.
  22. ASCEND Study Collaborative Group. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. The New England Journal of Medicine. 2018;379(16):1529–1539.

Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.

Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.